Treatment-naïve wet AMD patients who have longer intervals between initial symptom onset and first anti-VEGF injection may have worse long-term visual outcomes, according to a study presented at ARVO 2024. A total of 42 eyes of 42 patients with treatment-naïve wet AMD presenting to Massachusetts Eye & Ear Emergency Department (MEE ED) from 2009 to October 2023 were studied retrospectively. Time from symptom onset to first anti-VEGF injection ranged from 0 to 215 days. After adjusting for age, sex, baseline BCVA, number of injections, and medication, the interval between symptom onset and initial injection correlated with BCVA outcomes at 1-year, 2-year, and 3-year follow-up. Specifically, each additional day in the interval corresponded to a 0.01 increase in logMAR BCVA at 1-year follow-up (P<.001). Time from ED visit to injection, which was on average 7.7 days (range 0-42), was not significantly associated with BCVA outcomes. The researchers concluded that their findings support the importance of prompt diagnosis, referral, and treatment.